Opdivo (nivolumab) Demonstrates Long Term Survival Benefit in Patients with Previously Treated Non-Squamous Non-Small Cell Lung Cancer in CheckMate -057
September 27, 2015 at 18:10 PM EDT
Bristol-Myers Squibb Company (NYSE: BMY) today announced longer term (18 month) survival data from CheckMate -057, an open-label, ...
